OMCL

EX-99.1

2 exhibit991q1-26.htm

EX-99.1

Document

Exhibit 99.1

Contact:Omnicell, Inc.

Investor Relations4220 North Freeway

Investor.Relations@omnicell.comFort Worth, TX 76137

Omnicell Announces First Quarter 2026 Financial Results

Omnicell delivers strong first quarter 2026 financial results

Raises full year 2026 non-GAAP EBITDA and non-GAAP EPS guidance

Customer engagement underway for Omnicell Titan XT and OmniSphere

FORT WORTH, Texas -- April 28, 2026 -- Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell,” “we,” “our,” or the “Company”), a leading healthcare technology provider focused on empowering autonomous medication management, today reported financial results for the first quarter ended March 31, 2026.

First quarter results reflected strong execution across the business, supported by demand for Omnicell’s connected device portfolio and solid performance across the Company’s core points of care solutions. We believe that performance during the quarter underscores the durability of Omnicell’s model, supported by disciplined cost management which contributed to improved profitability.

“We delivered a strong start to 2026, driven by solid execution and sustained demand for our points of care solutions,” said Randall Lipps, chairman, president, chief executive officer, and founder of Omnicell. “As care environments continue to become more complex, we see that health systems are prioritizing reliability, efficiency, and standardization in medication workflows. During the quarter, we continued to advance solutions designed to support health systems as they manage increasingly complex medication workflows, optimize the medication supply chain, and improve operational efficiency while enhancing both the caregiver and patient experience.”

“At the same time, we advanced the next phase of our platform evolution,” Lipps added. “Following the introduction of Omnicell Titan XT at ASHP, customer engagement is underway as health systems begin incorporating the platform into longer-term capital planning cycles. OmniSphere continues to mature as our enterprise, system-wide, cloud-native platform, built to enable greater visibility, analytics, and workflow intelligence across medication management. We believe Omnicell Titan XT and OmniSphere represent a meaningful long-term opportunity and provide a strong foundation for enterprise-wide intelligence, workflow optimization, and durable growth as adoption scales over time.”

Financial Results

Total revenues for the first quarter of 2026 were $310 million, up $40 million, or 15%, from the first quarter of 2025. The year-over-year increase in total revenues was driven by strength in our connected devices offerings, as well as increases in technical services, SaaS and Expert Services, and consumables revenues.

Total GAAP net income for the first quarter of 2026 was $11 million, or $0.25 per diluted share. This compares to GAAP net loss of $7 million, or $0.15 per diluted share, for the first quarter of 2025.

Total non-GAAP net income for the first quarter of 2026 was $25 million, or $0.55 per diluted share. This compares to non-GAAP net income of $12 million, or $0.26 per diluted share, for the first quarter of 2025.

Total non-GAAP EBITDA for the first quarter of 2026 was $45 million. This compares to non-GAAP EBITDA of $24 million for the first quarter of 2025.

1

Balance Sheet

As of March 31, 2026, Omnicell’s balance sheet reflected cash and cash equivalents of $239 million, total debt (net of unamortized debt issuance costs) of $168 million, and total assets of $2.0 billion. Cash flows provided by operating activities in the first quarter of 2026 totaled $55 million. This compares to cash flows provided by operating activities totaling $26 million in the first quarter of 2025.

As of March 31, 2026, the Company had $350 million of availability under its revolving credit facility with no outstanding balance.

Corporate Highlights

•The Omnicell Titan XT Automated Dispensing System and OmniSphere were showcased at the American Organization for Nursing Leadership (AONL) 2026 Annual Meeting, where nursing leaders had the opportunity to explore this next generation technology and how it is expected to minimize the time nurses spend locating medications and enable safer medication administration.

•Omnicell connected with global pharmacy leaders at the 30th EAHP Congress, the annual gathering for the European Association of Hospital Pharmacists to showcase how intelligence-driven solutions are transforming medication and supply management.

•In March 2026, the Company launched the Omnicell Customer Community, a new virtual networking space that provides a forum for customers to collaborate, share insights, and gain peer-to-peer best practices.

2026 Guidance

The table below summarizes Omnicell’s second quarter and updated full year 2026 guidance. Given the strength of our first quarter 2026 profitability performance and ongoing focus on spend discipline, we are increasi

omcl-202602050000926326false00009263262026-02-052026-02-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C.  20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):  February 5, 2026

OMNICELL, INC.

(Exact name of registrant as specified in its charter)

Delaware000-3304394-3166458 (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification Number)

4220 North Freeway Fort Worth, TX 76137 (Address of principal executive offices, including zip code)

(877) 415-9990 (Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading SymbolName of each exchange on which registered Common Stock, $0.001 par valueOMCLNASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition. On February 5, 2026, Omnicell, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2025. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits

Exhibit NumberExhibit Description 99.1Press release entitled “Omnicell Announces Fiscal Year and Fourth Quarter 2025 Financial Results” dated February 5, 2026

104Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

OMNICELL,  INC.

Date: February 5, 2026 /s/ H. Baird Radford, III Baird Radford Executive Vice President and Chief Financial Officer

omcl-202510300000926326false00009263262025-10-302025-10-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C.  20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):  October 30, 2025

OMNICELL, INC.

(Exact name of registrant as specified in its charter)

Delaware000-3304394-3166458 (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification Number)

4220 North Freeway Fort Worth, TX 76137 (Address of principal executive offices, including zip code)

(877) 415-9990 (Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading SymbolName of each exchange on which registered Common Stock, $0.001 par valueOMCLNASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition. On October 30, 2025, Omnicell, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025 and updating its guidance for the full year 2025. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits.

Exhibit NumberExhibit Description 99.1Press release entitled “Omnicell Announces Third Quarter 2025 Financial Results” dated October 30, 2025

104Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

OMNICELL, INC.

Date: October 30, 2025 /s/ H. Baird Radford, III Baird Radford Executive Vice President and Chief Financial Officer